Search results
Results from the WOW.Com Content Network
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
TB Alliance was conceived at a February 2000 meeting in Cape Town, South Africa, where 120 representatives from academia, industry, major government agencies, non-governmental organizations and donors gathered to discuss the problems of tuberculosis treatment. Participants stressed the need for faster-acting, novel TB drugs and highlighted the ...
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
During the American colonial era, tuberculosis was a major health concern in the Philippines. In 1910, a regional meeting was held in Manila and it was reported the mortality of the disease is estimated to be 40,000. [4] The health situation led to the establishment of the Philippine Islands Anti-Tuberculosis Society on July 29, 1910.
The Global Fund’s investments have reduced deaths from HIV, tuberculosis, and malaria by 61% since 2002, saving 65 million lives. [25] Recent efforts include lowering the cost of key treatments for drug-resistant TB by 55% and first-line HIV medications by 25%, while introducing a more effective insecticide-treated mosquito net. [26]
For active tuberculosis it is used with other antimycobacterial medications. [1] For latent tuberculosis it may be used by itself when the exposure was with drug-resistant TB. [1] Rifabutin was approved for medical use in the United States in 1992. [1] It is on the World Health Organization's List of Essential Medicines. [3]
Roughly one-quarter of the world's population has been infected with M. tuberculosis, [6] with new infections occurring in about 1% of the population each year. [11] However, most infections with M. tuberculosis do not cause disease, [169] and 90–95% of infections remain asymptomatic. [87] In 2012, an estimated 8.6 million chronic cases were ...
There are dangers, however, of a rise of antibiotic-resistant TB. The TB treatment regimen is lengthy, and difficult for poor and disorganized people to complete, increasing resistance of bacteria. [24] Antibiotic-resistant TB is also known as "multidrug-resistant tuberculosis." "Multidrug-resistant tuberculosis" is a pandemic that is on the rise.